Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply.
- DOI
- 10.1016/s2213-8587(21)00326-0
- Published
- 2022 Feb
- Container
- The lancet. Diabetes & endocrinology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-21-00326-0,
title = {Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply.},
author = {Kosiborod MN and Esterline R and Oscarsson J and Gasparyan SB and Furtado RHM and Verma S and Berwanger O},
year = {2022},
journal = {The lancet. Diabetes \& endocrinology},
doi = {10.1016/s2213-8587(21)00326-0},
url = {https://doi.org/10.1016/s2213-8587(21)00326-0}
}RIS
TY - JOUR TI - Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply. AU - Kosiborod MN AU - Esterline R AU - Oscarsson J AU - Gasparyan SB AU - Furtado RHM AU - Verma S AU - Berwanger O PY - 2022 JO - The lancet. Diabetes & endocrinology DO - 10.1016/s2213-8587(21)00326-0 UR - https://doi.org/10.1016/s2213-8587(21)00326-0 ER -
APA
MN, K., R, E., J, O., SB, G., RHM, F., S, V., & O, B. (2022). Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply.. The lancet. Diabetes & endocrinology. https://doi.org/10.1016/s2213-8587(21)00326-0
Source records
- pubmed · retrieved 2026-09-26T10:40:56.576Z
- europe-pmc · retrieved 2026-09-26T10:40:56.583Z